Results 241 to 250 of about 68,677 (270)

Rethinking Mitochondrial Parkinson's Disease in the α‐Synuclein Seed Amplification Assays Era

Movement Disorders, EarlyView.
Marco Percetti, Vidal Yahya, Alessio Di Fonzo, Edoardo Monfrini   +3 more
wiley   +1 more source

Rare‐Variant Burden across Lysosomal Genes Implicates Sialylation and Ganglioside Metabolism in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Lysosomal dysfunction is central to Parkinson's disease (PD) pathogenesis, with GBA1 representing the strongest established genetic risk factor. Numerous other genes involved in lysosomal sphingolipid, glycosphingolipid, and ceramide metabolism have been proposed as contributors to PD, highlighting the need for genetic analyses ...
Konstantin Senkevich, Sitki Cem Parlar, Cloe Chantereault, Lang Liu, Eric Yu, Uladzislau Rudakou, Jamil Ahmad, Jennifer A. Ruskey, Farnaz Asayesh, Dan Spiegelman, Cheryl Waters, Oury Monchi, Yves Dauvilliers, Nicolas Dupré, Lior Greenbaum, Sharon Hassin‐Baer, Irina Miliukhina, Alla Timofeeva, Anton Emelyanov, Sofya Pchelina, Roy N. Alcalay, Ziv Gan‐Or   +21 more
wiley   +1 more source

Clinically reported covert cerebrovascular disease and risk of neurological disease: a whole-population cohort of 367 988 people using natural language processing. [PDF]

J Neurol Neurosurg Psychiatry
Iveson MH, Mukherjee M, Davidson EM, Zhang H, Sherlock L, Ball EL, Mair G, Hosking A, Whalley H, Poon MTC, Wardlaw JM, Kent DM, Tobin R, Grover C, Alex B, Whiteley W.   +15 more
europepmc   +1 more source

Plasma p‐tau217 Versus p‐tau181 in Parkinson's Disease: Differential Associations with Alzheimer's Disease‐Related Neurostructural Changes and Cognitive Function

Movement Disorders, EarlyView.
Abstract Background Plasma phosphorylated‐tau at threonine‐217 (p‐tau217) and threonine‐181 (p‐tau181) are scalable, minimally invasive biomarkers of Alzheimer's disease (AD) pathology. In Parkinson's disease (PD), AD co‐pathology may contribute to its clinical heterogeneity.
Eleonora Fiorenzato, Simone Cauzzo, Giulia Musso, Roberta Biundo, Chiara Ceolin, Chiara Cosma, Carmelo Alessandro Fogliano, Wassilios G. Meissner, Valentina Misenti, Stefania Moz, Maria Laura Nasi, Francesca Vianello, Renzo Manara, Martina Montagnana, Giuseppe Sergi, Angelo Antonini, on behalf of the OPA Working Group   +16 more
wiley   +1 more source

Novel Compounds as TREM2 Modulators for Treating Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, and Nasu-Hakola Disease. [PDF]

ACS Med Chem Lett
Sabnis RW, Sabnis AR.
europepmc   +1 more source

Association between the use of anti-herpetic drugs and subsequent initiation of Alzheimer's disease drug treatment: Dutch population-based inception cohort study. [PDF]

BMJ Open
Alghamdi A, Balafas S, Bos JHJ, van Munster BC, Rafie K, Dolga AM, Hak E.   +6 more
europepmc   +1 more source

Overcoming the diagnostic gap in mild cognitive impairment in Parkinson's disease: a pilot study employing a machine learning-/augmented reality-based digital biomarker. [PDF]

Front Aging Neurosci
Poplawska-Domaszewicz K, Streel E, Brek A, Miśko N, Kosińska E, Metta V, Odin P, Antonini A, Biundo R, Fiorenzato E, Wu K, Chopra S, Haridas S, Tarnanas I, Griffin N, Brugada-Ramentol V, Iulita MF, Jones M, Michalak S, Kozubski W, Ray Chaudhuri K.   +20 more
europepmc   +1 more source

No Evidence for an Association Between DIP2B Repeat Expansion and Neurological Disease

Movement Disorders, EarlyView.
Chia‐Ying Ko, Leon Schütz, Thomas Braun, Elena Buena‐Atienza, Nicolas Casadei, Danique Beijer, Ludger Schöls, Tobias B. Haack, Stephan Ossowski, Holger Hengel   +9 more
wiley   +1 more source